China Medical System Holdings Ltd. engages in the production, marketing, promotion, and sale of drugs. The firm's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The firm distributes its products within domestic market and to overseas markets.
根據最新的財務報表(Form-10K),China Medical System Holdings Limited 的總資產為 $0,淨isProfitable}為 $0
CHSYF 的關鍵財務比率是什麼?
China Medical System Holdings Limited 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
China Medical System Holdings Limited 的收入按細分市場或地理位置如何劃分?
China Medical System Holdings Limited 最大收入來源為 Integrated Line,在最近的收益報告中收入為 7,750,902,245。就地區而言,China 是 China Medical System Holdings Limited 的主要市場,收入為 8,906,169,113。
China Medical System Holdings Limited 是否盈利?
無,根據最新的財務報表,China Medical System Holdings Limited 的淨損失為 $0